ANVISA Approves New HIV Prevention Medication
Agência Nacional de Vigilância Sanitária (ANVISA), or the Brazilian Health Regulatory Agency/National Health Surveillance Agency, approved Apretude® (cabotegravir), in both tablet and injectable dosage forms, on June 05, 2023, for the prevention of Human Immunodeficiency Virus (HIV) viral transmission. (New Drug for HIV Prevention) Apretude® is only recommended for individuals who weigh at least thirty-five (35) kilograms.